# Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF

> **NCT02007720** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 876 (actual)

## Conditions studied

- Acute Heart Failure

## Interventions

- **DRUG:** Serelaxin
- **DRUG:** Placebo
- **OTHER:** Standard of CareTherapy

## Key facts

- **NCT ID:** NCT02007720
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03-12
- **Primary completion:** 2017-03-27
- **Final completion:** 2017-06-16
- **Target enrollment:** 876 (ACTUAL)
- **Why stopped:** Study was terminated based on results from pivotal adult AHF study CRLX030A2301
- **Last updated:** 2019-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02007720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02007720, "Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02007720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*